Recombinant Human FAD-dependent oxidoreductase domain-containing protein 1 (FOXRED1)

What is the genetic and protein structure of FOXRED1?

The FOXRED1 gene is located on the q arm of chromosome 11 in position 14.2 (11q14.2) and consists of 12 exons . The gene produces a 53.8 kDa protein composed of 486 amino acids, with alternatively spliced transcript variants also observed .

The protein structure of FOXRED1 contains an oxidoreductase FAD-binding domain and shows homology to several FAD-binding proteins including dimethylglycine dehydrogenase, sarcosine dehydrogenase, L-pipecolic acid oxidase, peroxisomal sarcosine oxidase, and pyruvate dehydrogenase regulatory subunit . Researchers should note that structural similarities to sarcosine oxidase (MSOX) suggest that tyrosine residues Y410 and Y411 likely constitute the site of covalent attachment for FAD . Additionally, a phenyl moiety at position 359 appears critical for proper function of the protein .

When performing structural studies, protein modeling approaches using SWISS-MODEL with BLAST and HHBlits have proven useful for analyzing how missense mutations might affect FOXRED1 structure and function .

How is FOXRED1 targeted to mitochondria?

To investigate mitochondrial targeting experimentally, researchers should employ subcellular fractionation techniques followed by western blotting to detect FOXRED1 in mitochondrial fractions. Comparing the molecular weight of mitochondrial FOXRED1 with the cytosolic precursor can help determine if cleavage occurs. Additionally, mutagenesis of the putative N-terminal targeting sequence followed by localization studies using fluorescent tags can clarify the importance of this sequence for proper targeting.

What diseases are associated with FOXRED1 mutations?

Mutations in the FOXRED1 gene have been primarily associated with Leigh syndrome and infantile-onset mitochondrial encephalopathy . The clinical manifestations can vary significantly, with recent research expanding the known clinical spectrum. For example, case studies have identified ataxia, epilepsy, and psychomotor developmental delay in patients carrying specific FOXRED1 variants including c.920G>A (p.Gly307Glu) and c.733+1G>A .

Researchers investigating FOXRED1-related disorders should be aware that the variability in clinical presentation necessitates careful phenotype-genotype correlation studies and functional validation of newly identified variants.

How can researchers assess pathogenicity of FOXRED1 variants?

A multi-faceted approach is recommended for determining pathogenicity of FOXRED1 variants:

• In silico analysis: Utilize evolutionary conservation metrics (GERP, PhyloP, phastCons), pathogenicity prediction tools (MutationTaster, FATHMM, DANN, SIFT, Provean), and minor allele frequency (MAF) data to initially assess variant significance .

• Biochemical analysis: Measure complex I activity in patient samples (fibroblasts, muscle biopsies) to confirm mitochondrial dysfunction .

• Protein analysis: Perform SDS-PAGE and blue native PAGE immunoblot analysis to assess FOXRED1 protein levels and complex I assembly, respectively .

• Functional complementation: Implement rescue experiments by expressing wild-type FOXRED1 in patient-derived cells to determine if defects can be reversed.

Recent research has demonstrated how these approaches can be integrated, showing that variants such as p.Gly307Glu affect the steady-state level of complex I holoenzyme in patient fibroblasts, confirming pathogenicity and revealing the molecular mechanism behind disease manifestation .

What techniques are recommended for assessing FOXRED1 enzymatic activity?

Several complementary approaches can be used to assess FOXRED1 enzymatic activity, drawing from methodologies used to study related FAD-dependent enzymes:

• DCPIP (2,6-dichlorophenolindophenol) reduction assay: This spectrophotometric method measures the reduction of DCPIP, which acts as an electron acceptor in FAD-dependent oxidation reactions. The assay provides a qualitative assessment of enzyme activity after relatively long incubation periods .

• Peroxidase-coupled assays: These assays utilize peroxidase and o-dianisidine to detect hydrogen peroxide production during FAD enzyme activity with oxygen as an electron acceptor. This approach helps determine if the enzyme efficiently uses molecular oxygen as an electron acceptor .

• Coupled enzymatic assays: For specific product detection, researchers can employ secondary enzymes that react with the products of FOXRED1 activity. For example, alcohol dehydrogenase (ADH) coupled with NADH can detect aldehyde formation, while glutamate dehydrogenase (GDH) can detect ammonia release .

• Kinetic analysis: Michaelis-Menten kinetics should be determined by measuring reaction rates at varying substrate concentrations. Parameters such as Km, kcat, and catalytic efficiency (kcat/Km) provide important insights into substrate specificity and reaction efficiency .

When analyzing FOXRED1 activity, researchers should note that the catalytic efficiency (kcat/Km) of related FAD-dependent enzymes typically ranges from 2×10³ to 5×10⁴ M⁻¹s⁻¹, with Km values between 0.2-5 mM .

How can researchers analyze FOXRED1's role in complex I assembly?

To investigate FOXRED1's role in complex I assembly, researchers should implement the following techniques:

• Blue Native PAGE (BN-PAGE): This technique separates native protein complexes according to size while preserving their interactions. Use BN-PAGE followed by immunoblotting with antibodies against complex I subunits to visualize assembly intermediates and the fully assembled complex I .

• Immunoprecipitation: Perform co-immunoprecipitation experiments with tagged FOXRED1 to identify interaction partners during complex I assembly.

• Pulse-chase experiments: These can reveal the temporal sequence of complex I assembly and the stage at which FOXRED1 is involved.

• RNA interference or CRISPR-Cas9 gene editing: Knockdown or knockout of FOXRED1 followed by analysis of complex I assembly intermediates can identify the specific steps requiring FOXRED1.

• Complementation studies: Express wild-type or mutant FOXRED1 in FOXRED1-deficient cells to assess rescue of complex I assembly defects.

In particular, mitochondrial fractions from patient and control cell lines should be used for these analyses, with the native mitochondrial complexes solubilized with appropriate detergents (e.g., 2% dodecyl maltoside) before BN-PAGE separation .

How does the FAD-binding mechanism in FOXRED1 compare to other oxidoreductases?

FOXRED1 belongs to a family of FAD-dependent oxidoreductases, and understanding its FAD-binding mechanism requires comparative analysis with related enzymes. Based on structural similarities to sarcosine oxidase (MSOX), FOXRED1's tyrosine residues Y410 and Y411 likely form the covalent attachment site for FAD . This mechanism can be investigated through:

• Site-directed mutagenesis: Alter key residues (Y410, Y411) and assess FAD binding and enzymatic activity.

• Spectroscopic analysis: Compare absorption spectra of wild-type and mutant proteins to detect changes in FAD binding.

• Crystallography or cryo-EM: Determine the three-dimensional structure of FOXRED1 with bound FAD to visualize the binding pocket.

• Comparative analysis: Examine the catalytic parameters of FOXRED1 against other FAD-dependent enzymes. For context, glycine oxidase from B. licheniformis oxidizes glycine with a kcat/Km of 340 M⁻¹s⁻¹ and Km of 0.9 mM, while monomeric sarcosine oxidase from Bacillus sp. B-0618 oxidizes sarcosine with a kcat/Km of 10,100 M⁻¹s⁻¹ and Km of 4.5 mM .

Understanding FOXRED1's FAD-binding mechanism is crucial for interpreting how mutations might affect its function in disease states.

What methods can resolve contradictory findings about FOXRED1's mitochondrial targeting mechanism?

The literature contains contradictory information regarding FOXRED1's mitochondrial import mechanism, with some evidence suggesting import dependent on membrane potential while other findings point to a cleavable N-terminal localization sequence . Researchers can address this discrepancy through:

• Import assays with uncouplers: Perform in vitro mitochondrial import assays in the presence of compounds that dissipate the membrane potential (e.g., CCCP) to determine the dependence on membrane potential.

• N-terminal deletion constructs: Create FOXRED1 constructs lacking the putative 23-amino acid targeting sequence to assess localization.

• Mass spectrometry: Compare the mass of mature mitochondrial FOXRED1 with the predicted mass of the full-length protein to determine if processing occurs.

• Pulse-chase experiments: Track the fate of newly synthesized FOXRED1 to detect potential processing during import.

• In vitro processing assays: Incubate recombinant FOXRED1 with isolated mitochondrial processing peptidase (MPP) to test for cleavage.

A combination of these approaches will help resolve the contradictory findings and establish the actual mechanism of FOXRED1 mitochondrial targeting.

How can researchers reconcile variable clinical presentations with similar FOXRED1 mutations?

The clinical variability observed in patients with FOXRED1 mutations presents a challenge for researchers. To address this variability, the following approaches are recommended:

• Comprehensive genetic analysis: Look for modifier genes or second-site mutations that might influence disease expression.

• Tissue-specific expression studies: Examine FOXRED1 expression patterns across tissues in different patients to identify potential differences.

• Functional analysis of patient-derived cells: Compare complex I activity, assembly, and FOXRED1 function between patients with similar mutations but different clinical presentations.

• Epigenetic profiling: Investigate whether epigenetic differences might explain variable expressivity of the same mutation.

• Environmental factor assessment: Consider environmental factors (diet, medications, exposure to toxins) that might interact with FOXRED1 deficiency.

• Mitochondrial DNA background analysis: Examine whether differences in mitochondrial DNA haplogroups influence the phenotypic expression of FOXRED1 mutations.

This multi-faceted approach may reveal factors that modify the clinical expression of FOXRED1 mutations and explain the expanded clinical spectrum observed in recent research .

What experimental approaches can distinguish between primary and secondary effects of FOXRED1 deficiency?

When studying FOXRED1 deficiency, it's crucial to differentiate between direct consequences of FOXRED1 dysfunction and downstream secondary effects. Researchers can employ these strategies:

These approaches can help researchers develop more precise models of FOXRED1 function and its role in disease pathogenesis.

How might novel structural biology techniques advance understanding of FOXRED1 function?

Emerging structural biology techniques offer new opportunities to elucidate FOXRED1 function:

• Cryo-electron microscopy (cryo-EM): This technique can reveal the structure of FOXRED1 alone and in complex with assembly intermediates of complex I, providing insights into its chaperone function.

• Hydrogen-deuterium exchange mass spectrometry (HDX-MS): This approach can identify dynamic regions in FOXRED1 that undergo conformational changes during interaction with complex I components.

• Cross-linking mass spectrometry (XL-MS): By identifying residues in close proximity during protein-protein interactions, this technique can map the interaction surfaces between FOXRED1 and its partners.

• AlphaFold and other AI-based structure prediction tools: These computational approaches can generate increasingly accurate structural models for FOXRED1 and its variants, enabling prediction of functional consequences of mutations.

• Time-resolved structural studies: These can capture FOXRED1 in different conformational states during its catalytic cycle or chaperone function.

Researchers should consider that protein modeling techniques have already been useful in studying FOXRED1 variants, with SWISS-MODEL template libraries searched using BLAST and HHBlits for evolutionary-related structures matching the target sequence .

What are emerging therapeutic approaches targeting FOXRED1-related disorders?

Research into treatments for FOXRED1-related disorders is still developing, but several promising approaches warrant investigation:

• Gene therapy: Development of viral vectors for delivery of functional FOXRED1 to affected tissues, particularly the central nervous system for neurological manifestations.

• Enzyme replacement therapy: Engineering of FOXRED1 protein with mitochondrial targeting sequences and cell-penetrating peptides for delivery to mitochondria.

• Small molecule chaperones: Screening for compounds that can stabilize mutant FOXRED1 proteins and enhance their residual function.

• Metabolic bypass strategies: Identification of alternative metabolic pathways that can circumvent complex I deficiency caused by FOXRED1 mutations.

• Mitochondrial replacement therapy: For severe cases, investigating the potential of mitochondrial replacement techniques to prevent transmission of mitochondrial dysfunction.

• CRISPR-based approaches: Development of base editing or prime editing techniques for correction of common FOXRED1 mutations in affected tissues.

These therapeutic strategies should be evaluated in cellular and animal models of FOXRED1 deficiency before clinical translation.